Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates-Reference-Cited by-同舟云学术

Derivatives of the Antimalarial Drug Mefloquine Are Broad-Spectrum Antifungal Molecules with Activity against Drug-Resistant Clinical Isolates

Published:2020-02-21 Issue:3 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Montoya Marhiah C.¹²³,Beattie Sarah²³,Alden Kathryn M.²³,Krysan Damian J.²³

Affiliation:

1. Clinical and Translational Science Institute, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA

2. Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

3. Department of Microbiology, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA

Abstract

The antifungal pharmacopeia is critically small, particularly in light of the recent emergence of multidrug-resistant pathogens, such as Candida auris . Here, we report that derivatives of the antimalarial drug mefloquine have broad-spectrum antifungal activity against pathogenic yeasts and molds.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.02331-19

Reference58 articles.

1. Antifungal Drug Development: Challenges, Unmet Clinical Needs, and New Approaches

2. Candida auris: The Canary in the Mine of Antifungal Drug Resistance

3. Microevolution of Serial Clinical Isolates of Cryptococcus neoformans var. grubii and C. gattii